Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Biomarin Pharmaceutical Inc (BMRN)  
$88.63 1.44 (1.6%) as of 4:30 Fri 4/19


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 188,370,000
Market Cap: 16.70(B)
Last Volume: 1,778,607 Avg Vol: 1,398,026
52 Week Range: $76.22 - $99
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Drug Manufacturers - Other

Member Indexes:
    NASDAQ BIOTECHNOLOGY     NASDAQ COMPOSITE
    NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  811
Guru Rank Value     : 0.9
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Co.'s commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Naglazyme (galsulfase) the treatment of Mucopolysaccharidosis VI ; Palynziq (pegvaliase-pqpz) for adult patients with phenylketonuria; and Vimizim (elosulfase alpha) for the treatment of Mucopolysaccharidosis IV Type A.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 3,625
Total Buy Value $0 $0 $0 $314,469
Total People Bought 0 0 0 1
Total Buy Transactions 0 0 0 1
Total Shares Sold 159,588 261,929 319,053 656,089
Total Sell Value $13,270,852 $22,448,451 $27,661,182 $61,420,002
Total People Sold 5 6 7 7
Total Sell Transactions 10 20 27 56
End Date 2024-03-17 2023-12-15 2023-06-16 2022-06-16

   
Records found: 1303
  Page 50 of 53  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Davis George Eric VP, General Counsel   •       –      –    2007-02-22 4 OE $6.13 $79,690 D/D 13,000 13,000     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2007-02-22 4 AS $18.40 $18,400 D/D (1,000) 19,642     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2007-02-20 4 AS $16.96 $220,481 D/D (13,000) 20,642     -
   Aselage Steve SVP, Global Commercial Ops   •       –      –    2007-02-14 4 AS $20.00 $300,000 D/D (15,000) 2,829     -
   Aselage Steve SVP, Global Commercial Ops   •       –      –    2007-02-14 4 OE $7.16 $107,400 D/D 15,000 17,829     -
   Swiedler Stuart J SVP, Clinical Affairs   •       –      –    2007-01-03 4 AS $16.30 $203,700 D/D (12,500) 10,000     -
   Swiedler Stuart J SVP, Clinical Affairs   •       –      –    2007-01-03 4 OE $4.00 $50,000 D/D 12,500 22,500     -
   Lapalme Pierre Director   –       •      –    2006-12-12 4/A B $17.88 $17,880 D/D 1,000 5,500 2.39     -
   Lapalme Pierre Director   –       •      –    2006-12-12 4/A B $17.89 $19,676 I/I 1,100 1,100 2.1     -
   Lapalme Pierre Director   –       •      –    2006-12-12 4 B $17.88 $37,556 D/D 2,100 6,600 2.39     -
   Cooper Jeffrey H Chief Financial Officer   •       –      –    2006-12-06 4 AS $18.00 $261,000 D/D (14,500) 0     -
   Cooper Jeffrey H Chief Financial Officer   •       –      –    2006-12-06 4 OE $8.10 $117,450 D/D 14,500 14,500     -
   Aselage Steve SVP, Global Commercial Ops   •       –      –    2006-11-29 4 S $17.23 $86,150 D/D (5,000) 2,829     -
   Aselage Steve SVP, Global Commercial Ops   •       –      –    2006-11-29 4 OE $7.16 $35,800 D/D 5,000 7,829     -
   Swiedler Stuart J SVP, Clinical Affairs   •       –      –    2006-11-01 4 AS $15.92 $198,975 D/D (12,500) 10,000     -
   Swiedler Stuart J SVP, Clinical Affairs   •       –      –    2006-11-01 4 OE $4.00 $50,000 D/D 12,500 22,500     -
   Kakkis Emil D Chief Medical Officer   •       –      –    2006-10-31 4 B $3.43 $15,000 D/D 4,368 38,144 2.74     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2006-10-31 4 B $6.92 $19,103 D/D 2,761 33,642 2.81     -
   Baffi Robert SVP, Technical Operations   •       –      –    2006-10-31 4 B $3.43 $13,372 D/D 3,894 30,440 2.74     -
   Aselage Steve SVP, Global Commercial Ops   •       –      –    2006-10-31 4 B $6.92 $12,939 D/D 1,870 2,829 2.74     -
   Cooper Jeffrey H VP, Chief Financial Officer   •       –      –    2006-08-29 4 AS $16.00 $416,000 D/D (26,000) 0     -
   Cooper Jeffrey H VP, Chief Financial Officer   •       –      –    2006-08-29 4 OE $6.13 $198,780 D/D 26,000 26,000     -
   Klein Joseph III Director   –       •      –    2006-08-09 4 S $15.52 $310,320 D/D (20,000) 10,000     -
   Klein Joseph III Director   –       •      –    2006-08-09 4 OE $7.72 $231,600 D/D 30,000 30,000     -
   Lapalme Pierre Director   –       •      –    2006-08-07 4 B $15.35 $15,350 D/D 1,000 4,500 2.39     -
  1303 Records found
  Previous  50  51  52  53   
  Page 50 of 53
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us